

# Structure of major depressive disorder in adolescents and adults in the US general population

Femke Lamers, Marcy Burstein, Jian-ping He, Shelli Avenevoli, Jules Angst and Kathleen R. Merikangas

# **Background**

Although techniques such as latent class analysis have been used to derive empirically based subtypes of depression in adult samples, there is limited information on subtypes of depression in youth.

#### **Aims**

To identify empirically based subtypes of depression in a nationally representative sample of US adolescents, and to test the comparability of subtypes of depression in adolescents with those derived from a nationally representative sample of adults.

#### Method

Respondents included 912 adolescents and 805 adults with a 12-month major depressive disorder, selected from the National Comorbidity Survey Adolescent Supplement and the National Comorbidity Survey Replication samples respectively. Latent class analysis was used to identify subtypes of depression across samples. Sociodemographic and clinical correlates of

derived subtypes were also examined to establish their validity.

#### Results

Three subtypes of depression were identified among adolescents, whereas four subtypes were identified among adults. Two of these subtypes displayed similar diagnostic profiles across adolescent and adult samples (P=0.43); these subtypes were labelled 'severe typical' (adults 45%, adolescents 35%) and 'atypical' (adults 16%, adolescents 26%). The latter subtype was characterised by increased appetite and weight gain.

# Conclusions

The structure of depression observed in adolescents is highly similar to the structure observed in adults. Longitudinal research is necessary to evaluate the stability of these subtypes of depression across development.

# **Declaration of interest**

None.

Abundant evidence from prospective cohort studies of youth has indicated that the symptoms of depression emerge in childhood and adolescence. 1-6 The symptomatic manifestations of depression in both clinical and community studies of adolescents resemble the presentation found among adults.<sup>7-9</sup> Developmental differences in the symptoms of depression may nevertheless exist, 10 and there is some evidence that behavioural and somatic symptoms may be more prominent, and psychomotor symptoms less common, among children and adolescents.<sup>7,8,11–13</sup> Based on the widespread consensus regarding the heterogeneity of major depression, 14,15 there have been numerous efforts to identify distinct subtypes of major depression based on characteristics such as symptom clusters, age at onset, family history and course. 16-18 A comprehensive overview of different subtyping models of depression, including models based on aetiology, symptoms, time of onset, gender and treatment response, was recently published by Baumeister & Parker. 19 Statistical approaches such as factor analysis and latent class analysis (LCA) of data from both clinical and community samples of adults have shown that subtypes of depression were best discriminated by both severity and symptom profiles. 20,21 Studies of adults have found differences in treatment response, 22,23 biological correlates, <sup>24–26</sup> and course and stability of disorder, <sup>27,28</sup> between the various subtypes, particularly the melancholic and atypical subtypes specified in DSM-IV.

Despite abundant efforts to identify depression subtypes in adults, there has been little research on the expression of distinct subtypes of depression in adolescents.<sup>29</sup> To date, studies using LCA to examine subtypes of depression have been limited

to adult samples. Accordingly, the three goals of our study were to investigate the subtypes of major depressive disorder in a representative sample of US adolescents using LCA; to test the comparability of this structure across two nationally representative samples of adolescents and adults; and to examine sociodemographic and clinical correlates of derived subtypes across samples.

# Method

The National Comorbidity Survey Replication (NCS-R) is a nationally representative community household survey of 9282 non-institutionalised adults aged 18 years and over in the USA. Tace-to-face interviews were held at the respondents' homes between February 2001 and April 2003. The National Comorbidity Survey Adolescent Supplement (NCS-A) is an extension of the NCS-R that included young people aged 13–18 years who resided in the homes of NCS-R participants (n=879) and an additional school-based sample of young people (n=9244), yielding a total of 10123 adolescents. Interviews were conducted between February 2001 and January 2004. The Human Subjects Committees of Harvard Medical School and the University of Michigan approved all NCS-R and NCS-A procedures, and all participants gave informed consent prior to the interview.

All respondents with a 12-month major depressive disorder from NCS-A (n=912) and NCS-R (n=805) were selected for the analyses. We used 12-month disorders because

individuals without a current diagnosis may have more problems in accurately recalling their symptoms of depression. A non-hierarchical definition of major depressive disorder was used, in order to allow assessment of psychiatric comorbidity.

## Measures

The World Health Organization's Composite International Diagnostic Interview (CIDI) version 3.0 was used for diagnostic assessment of psychiatric disorders.<sup>33</sup> The CIDI is a fully structured interview administered by trained lay interviewers to generate DSM-IV diagnoses. The NCS-A used a modified version of the CIDI used in NCS-R for diagnostic assessment of psychiatric disorders.<sup>34</sup>

# **Depressive symptoms**

We included the nine DSM-IV symptoms of depression listed in the CIDI but separated weight changes from appetite changes, yielding a total of ten symptoms. All variables were coded as present or absent; however, variables for changes in weight, appetite, sleep and psychomotor activity included a further distinction between weight loss/gain, increased/decreased appetite, insomnia/hypersomnia and activation/retardation, leading to variables with three categories to better capture the differences in symptom profiles.

## Characteristics to describe latent classes

Sociodemographic variables including gender and age were collected in both surveys. Clinical characteristics included number of depressive symptoms, number of episodes and age at onset, derived from the CIDI; severity, measured with a modified version of the Quick Inventory of Depressive Symptomatology;<sup>35</sup> and 12-month comorbidity with DSM-IV psychiatric disorders assessed in the CIDI (mania, hypomania, dysthymia, generalised anxiety disorder, panic disorder, social phobia, agoraphobia, specific phobia, substance use disorder, any binge eating disorder). Family histories of depression and mania were assessed. Further, we collected information on treatment in the past year for emotional or behavioural problems. We created variables to indicate whether participants had received any mental healthcare (out-patient mental health clinic, mental health professional, drug or alcohol clinic, admission to psychiatric hospital or other mental health facility) and any mental or medical healthcare (general medical care, any mental healthcare, and any school services for the NCS-A sample) during the previous year.

Several functional and health indicators were used to describe latent classes. The World Health Organization Disability Assessment Schedule (WHO-DAS) was used to assess functional impairment during the past month (NCS-R only),36 and we created a dichotomous variable indicating which participants had severe or very severe disability (defined as scoring more than 6 on a scale of 0–10, based on the Sheehan Disability Scale<sup>37</sup>). We calculated body mass index (BMI) in kg/m<sup>2</sup> based on selfreported weight and height. Presence of somatic disorders was based on chronic conditions assessed in the US National Health Interview Survey.<sup>38</sup> Respondents were asked whether they had ever experienced each of the conditions in this checklist. We included the following conditions: heart attack and heart disease (NCS-R only), diabetes or high blood glucose level, high blood pressure (NCS-R only), migraine, and other headaches.

# Statistical analysis

Latent class analyses were performed using Mplus version 6.1 for Windows.<sup>39</sup> In LCA it is assumed that an unobserved, latent categorical variable (i.e. class) explains the association among a set of observed variables (i.e. symptoms). It computes two sets of parameters: latent class probabilities or prevalences, and conditional probabilities (estimated probabilities of observed variables given that the individual is a member of that class). Ten categorical variables measuring depressive symptoms (as described earlier) served as latent class indicators, and models with one to five classes were estimated. The final model was chosen based on the Bayesian information criterion (BIC, smallest value preferred), the sample size-adjusted BIC (smallest value preferred), entropy (highest value preferred) and interpretability of the derived classes. 40-42 Respondents were assigned to their most likely class based on posterior probabilities, classes were given subjective labels based on symptom probabilities, and correlates of classes were then evaluated in SAS version 9.2 (SAS Institute, Cary, North Carolina, USA) for Windows, separately for adolescents and adults. Class comparisons within samples were performed for correlates with a significant main effect (P < 0.05), and further post hoc tests examined differences between NCS-A and NCA-R classes. All analyses corrected for the complex sampling design and were weighted to adjust for differential probabilities of selection, non-response and post-stratification.

# **Results**

The sociodemographic characteristics of the two study samples are presented in Table 1.

Table 1         Sociodemographic chara           and adult samples	<b>ble 1</b> Sociodemographic characteristics of the adolescent d adult samples		
	Adolescents NCS-A (n = 912) <sup>a</sup>	Adults NCS-R ( <i>n</i> = 805) <sup>a</sup>	
Female, weighted % (s.e.)	69.0 (2.2)	64.2 (2.0)	
Age, years: weighted % (s.e.) 13–14 15–16 17–18 18–29 30–44 45–59 ≥60	26.3 (2.9) 46.4 (2.6) 27.3 (2.1)	28.4 (1.9) 37.1 (1.7) 26.1 (1.6) 8.4 (1.0)	
Education, years: weighted mean (s.e.) Ethnicity, weighted % (s.e.) Black Hispanic Other White	9.2 (0.1) 15.2 (1.5) 17.2 (1.9) 5.1 (1.2) 62.4 (2.7)	13.0 (0.1) 10.4 (1.5) 10.1 (1.7) 5.2 (0.7) 74.3 (2.7)	
Marital status, weighted % (s.e.) Married/cohabitating Separated/widowed/divorced Never married	NA NA NA	42.6 (2.1) 27.0 (1.8) 30.4 (2.0)	
Employment, weighted % (s.e.) Working Student Homemaker Retired Other	1.7 (0.5) 94.4 (1.3) 0 0 3.9 (1.2)	63.4 (2.3) 3.0 (0.8) 5.7 (0.9) 7.5 (1.0) 20.3 (1.9)	

NA, not applicable; NCS-A, National Comorbidity Survey Adolescent Supplement; NCS-R, National Comorbidity Survey Replication.
a. Unweighted.

## **Model selection**

In the NCS-A sample both the BIC and the sample size-adjusted BIC were smallest in the three-class model, which was therefore chosen as the final model. In the NCS-R sample the BIC was smallest in a three-class model, whereas the four-class model yielded the smallest sample size-adjusted BIC and higher entropy than the three-class model (Table 2); additionally, the four-class model more closely approximated subtypes identified in previous research, <sup>20,21,43</sup> and the current distinctions between atypical and typical depressive disorder subtypes in the DSM-IV. The four-class model was therefore chosen in the adult sample.

# **Class description**

#### Adolescents

In the adolescent sample (NCS-A) the first class identified was labelled 'moderate typical' (prevalence 39.9%) owing to a typical symptom pattern characterised by decreased appetite and insomnia (Fig. 1). This class had the lowest proportion of young people with suicidal thoughts. The second class was labelled 'severe typical' (prevalence 34.6%) owing to a typical symptom pattern including weight loss, and higher symptom probabilities than the 'moderate typical' class. The third class was labelled 'atypical' (prevalence 25.5%) as it presented an atypical symptom pattern marked by increased appetite and weight gain.

## Adults

In the NCS-R sample the first class was characterised by few changes in appetite or weight and psychomotor changes, and had a prevalence of 14.6%. This class was labelled 'moderate' owing to its moderately severe symptom pattern (Fig. 2). The second class, labelled 'moderate typical' because of its typical symptom pattern including weight loss, decreased appetite and insomnia, had a prevalence of 24.8%. The third class, 'severe typical' (prevalence 44.9%) had a typical symptom pattern but higher symptom probabilities and proportions of adults with insomnia and suicidal thoughts than the 'moderate typical' class. The fourth class, 'atypical' (prevalence 15.6%), had a distinct pattern of increased appetite and weight gain.

# Comparison of adults and adolescents

We performed additional multiple-group LCA simultaneously in NCS-A and NCS-R samples to test whether the observed class symptom profiles were similar across the samples. For this purpose, we ran an unrestricted model and a restricted model using the KNOWNCLASS-option in Mplus, and performed a -2 log-likelihood test. In the unrestricted model all parameters were estimated freely, whereas in the restricted model the probabilities of symptoms within classes were held equal across samples. Because the NCS-R sample had four classes and the NCS-A sample only three, we used a restriction to fix the prevalence of the additional NCS-R class to zero in the NCS-A sample. These analyses showed that the restricted model, where all three classes were held equal, was significantly different from the unrestricted model (P=0.03), but a model restricting only two classes was not significantly different (P = 0.43). These results indicate that the symptom profiles of the severe typical and atypical (but not the moderate typical) classes were the same across samples. Comparison of the prevalence rates of the adult severe typical and adult atypical classes with the prevalence rates of their adolescent counterparts showed that these rates differed significantly, with adolescents having a higher rate of the atypical subtype and a lower rate of severe typical subtype.

Table 2 Fit in	dices from the late	ent class analyse	es
	BIC	BIC <sub>ssa</sub>	Entropy
Adolescents			
1-class	9993.7	9949.2	
2-class	9702.2	9610.1	0.95
3-class	9648.9	9509.1	0.76
4-class	9712.2	9524.8	0.78
5-class	9758.3	9523.3	0.83
Adults			
1-class	8431.4	8386.9	
2-class	8013.9	7921.8	0.95
3-class	7956.1	7816.3	0.80
4-class	7997.9	7810.5	0.82
5-class	8056.1	7821.1	0.83
BIC, Bayesian inform	ation criterion; BIC <sub>ssa</sub> , sa	mple size-adjusted BIC	).

## **Correlates**

Adolescents

The sociodemographic, clinical and health correlates of the identified subtypes are presented in Tables 3 and 4. In adolescents, the atypical class had the highest proportion of female participants, and between-class differences were statistically significant. No other difference in demographic variables was observed. The number of symptoms was significantly higher in the severe typical class compared with the other two classes, but symptom severity was highest in the atypical class and significantly higher than in the moderate typical class. The proportions of adolescents with a positive family history of depression were significantly different between the adolescent classes, with both the severe typical and atypical classes having a higher proportion of young people with a positive family history relative to the moderate class.

Agoraphobia was differentially distributed across classes, with the severe typical class having double the prevalence rate of agoraphobia compared with the other two classes. Further, rates of any binge eating disorder were highest in the atypical class and lowest in the moderate class. No difference in treatment was observed across adolescent classes. In terms of health indicators, no difference in disability was found, but the atypical class had the highest BMI, and this was significantly higher than the moderate typical class. The percentage of adolescents who were overweight or obese (based on BMI *z*-score, >85th percentile) was also highest in the atypical group (45.6%  $\nu$ . 36.4–39.7%).

# Adults

In the adult sample, the proportion of women increased with increasing severity of classes. The highest proportion of women was found in the atypical class, and this proportion was significantly higher relative to all other classes. There were significant differences between classes in the number of symptoms present, with the severe typical class having the highest mean number of symptoms, followed by the atypical class. Severity scores for depression were also higher in the severe typical and atypical classes. Differences in number of episodes between classes were found, with the moderate typical class having the fewest episodes. This class further had the highest percentage of adults with early disorder onset (<12 years of age), whereas the moderate class had the lowest percentage of adults with early onset. No difference was found in family history of depression, but the severe typical class more frequently had a family history of mania than the moderate class.




Fig. 1 Symptom endorsement of subtypes in adolescents.




Fig. 2 Symptom endorsement of subtypes in adults.

With respect to comorbid disorders, there was a significant difference between classes in mania, with the highest rates observed in the atypical class. Hypomania was significantly different across adult classes, with the highest rate in the severe typical class and the lowest in the atypical class. Social phobia, agoraphobia and specific phobia were all significantly different across latent classes; highest prevalence rates for these disorders were observed in the severe typical class. Those in the atypical class were most likely to have received any healthcare, and those in the

severe typical class were most likely to have received any mental healthcare in the previous year.

Body mass index significantly differed across adult classes, with the atypical class having a significantly higher BMI than all other classes and also having the highest percentage of people with a BMI greater than  $25\,\mathrm{kg/m^2}$  (77.6% v. 54.2–59.2% in other subtypes). The WHO-DAS health functioning scale further showed highest disability in the severe typical class. Severity of the severe typical class was also distinguished by disability, with

	Class 1 Moderate typical	Class 2 Severe typical	Class 3 Atypical	$\chi^2$ /F-test P
Neighted, %	39.9 (2.0)	34.6 (2.6)	25.5 (2.5)	
Demographics				
Female, %	60.4 (3.9)	70.8 (2.7)	80.2 (4.0)	< 0.001 <sup>a,b</sup>
Age, years: %				0.11
13–14	31.6 (4.1)	27.2 (5.0)	16.6 (3.9)	
15–16	43.7 (3.8)	45.2 (4.4)	52.4 (5.1)	
17–18	24.7 (3.0)	27.7 (3.3)	30.9 (4.4)	
Clinical characteristics				
Number of symptoms, mean	6.7 (0.1)	8.2 (0.1)	7.9 (0.1)	< 0.0001 <sup>a,b</sup>
MDD severity (QIDS score), mean	14.2 (0.2)	14.7 (0.5)	15.5 (0.4)	0.001 <sup>b</sup>
lumber of episodes, %				0.12
0–1	23.4 (4.2)	15.9 (4.1)	10.3 (3.2)	
2–5	52.1 (5.9)	48.5 (3.6)	54.8 (6.7)	
>5	24.5 (4.5)	35.6 (4.2)	34.9 (6.0)	
Age at onset <12 years, %	43.5 (4.3)	45.1 (4.2)	35.4 (4.0)	0.23
Family history of MDD, %	18.8 (4.0)	32.0 (4.7)	41.8 (7.1)	0.007 <sup>a,b</sup>
Family history of mania, %	10.1 (3.7)	19.8 (4.9)	23.9 (6.3)	0.09
Treatment (past year), %				
Any healthcare	28.5 (4.2)	36.4 (5.8)	38.5 (4.6)	0.36
Any mental healthcare	22.2 (3.8)	33.0 (5.4)	35.1 (4.8)	0.13
Comorbid psychiatric disorders (past year), %				
Mania	3.9 (1.5)	4.4 (1.8)	4.6 (1.9)	0.95
Hypomania	9.1 (2.0)	13.5 (3.6)	12.8 (2.8)	0.47
Dysthymia	22.0 (3.5)	31.1 (5.3)	22.1 (3.9)	0.20
Generalised anxiety disorder	11.0 (2.6)	10.0 (2.4)	9.8 (2.5)	0.93
Panic disorder	5.0 (0.9)	7.0 (2.4)	6.6 (1.8)	0.67
Social phobia	20.1 (2.4)	27.6 (4.9)	27.2 (4.4)	0.31
Agoraphobia	4.4 (1.1)	9.8 (2.7)	3.8 (1.4)	0.01 <sup>a,c</sup>
Specific phobia	26.6 (2.8)	41.0 (6.6)	35.4 (5.4)	0.11
Substance use disorder	20.6 (2.8)	25.3 (4.4)	19.6 (3.9)	0.51
Any binge eating disorder	4.6 (1.3)	10.2 (4.2)	19.3 (5.3)	0.02 <sup>b</sup>
Functional and health indicators				
VHO-DAS functioning	=	-	=-	
Sheehan Disability Scale (% severe/very severe), mean	60.5 (4.3)	67.4 (3.6)	71.9 (3.7)	0.11
Body mass index, kg/m²: mean	22.3 (0.3)	23.0 (0.4)	24.4 (0.7)	< 0.0001 <sup>b</sup>
Chronic diseases, %				
Diabetes	0.8 (0.5)	0.9 (0.3)	1.8 (1.2)	0.52
Migraine	12.4 (2.7)	12.0 (3.0)	13.1 (3.1)	0.97
Other headache	29.9 (3.6)	36.7 (3.8)	35.4 (4.4)	0.40

a. Class 1 significantly different from class 2, P < 0.05.

significantly greater role disability in the severe typical  $\nu$ . the moderate typical class.

# Comparison of correlates in adolescents and adults

Several similarities were observed between the adolescent and adult samples. In both samples the proportion of female participants was highest in the atypical class and was similar across samples (P = 0.88). In both samples the number of symptoms was highest in the severe typical class and the symptom severity score was highest in the atypical class. Comparisons of similar classes between adolescents and adults revealed no significant difference in number of symptoms and symptom severity between classes (data not shown). In both samples, BMI was highest in the atypical class, and there was no observed difference in chronic conditions. There were, however, several differences in correlates between the adolescent and adult samples: differences in number of episodes, age at onset and treatment between classes were observed only in the adult sample.

# Discussion

This study provides novel information on the structure of depression in nationally representative samples of US adolescents and adults. The subtypes identified in these analyses suggest that both symptom patterns and severity of depressive symptoms are sources of heterogeneity in major depressive disorder. The central importance of symptoms that are somatic in quality (such as changes in appetite, weight, sleep and fatigue) in discriminating depressive subtypes has major implications for our understanding of the biologic pathways, treatment and opportunities for prevention of the consequences of this major public health problem in American youth. As in previous work, 8,11,13 our results indicate that the structure of depression is largely similar across adolescent and adult age groups. Among adolescents, three distinct subtypes of depression were derived: one defined by a typical symptom presentation and moderate severity (moderate typical), one characterised by a typical symptom presentation and high severity (severe typical) and a third marked by an

b. Class 1 significantly different from class 3, P<0.05. c. Class 2 significantly different from class 3, P<0.05.

Weighted % (s.e.)         14.6 (1.3)         24.8 (1.5)         44.9 (1.8)         15.6 (1.3)           Demographics           Female, %         51.9 (4.0)         57.5 (3.6)         66.5 (3.0)         79.4 (3.6)           Age, years: %         37.4 (5.3)         31.5 (3.6)         24.8 (2.5)         26.0 (3.9)           30-44         36.7 (4.8)         34.1 (3.8)         38.3 (3.3)         38.8 (4.8)           45-59         16.4 (3.0)         23.2 (3.2)         39.4 (3.0)         30.1 (3.7)           Chinical characteristics         Number of symptoms, mean         6.3 (0.1)         6.8 (0.1)         9.0 (0.1)         7.9 (0.2)           MDD severity (QIDS score), mean         14.3 (0.4)         13.6 (0.3)         16.2 (0.2)         16.3 (0.3)           Number of episodes, %         9.5 (3.0)         23.0 (3.2)         15.2 (2.5)         12.0 (3.0)           0-1         9.5 (3.0)         23.0 (3.2)         15.2 (2.5)         12.0 (3.0)           2-5         45.1 (5.9)         49.3 (3.7)         37.5 (4.1)         41.9 (6.8)           > 5         45.4 (6.4)         27.7 (3.6)         47.3 (4.8)         46.0 (7.0)           Age at onset (<12 years), %         18.9 (3.5)         31.8 (2.7)         25.6 (4.5)         20.8 (3.3)	χ²/F-test P	Class 4 Atypical	Class 3 Severe typical	Class 2 Moderate typical	Class 1 Moderate	
Female, %		15.6 (1.3)	44.9 (1.8)	24.8 (1.5)	14.6 (1.3)	Weighted % (s.e.)
Age, years: %  18–29 37.4 (5.3) 31.5 (3.6) 24.8 (2.5) 26.0 (3.9) 30-44 36.7 (4.8) 34.1 (3.8) 38.3 (3.3) 38.8 (4.8) 45–59 16.4 (3.0) 23.2 (3.2) 39.4 (3.0) 30.1 (3.7) ≥ 60 9.5 (2.4) 11.2 (2.5) 7.7 (1.6) 5.1 (2.1)  Clinical characteristics  Number of symptoms, mean 6.3 (0.1) 6.8 (0.1) 9.0 (0.1) 7.9 (0.2)  MDD severity (QIDS score), mean 14.3 (0.4) 13.6 (0.3) 16.2 (0.2) 16.3 (0.3)  Number of episodes, %  0-1 9.5 (3.0) 23.0 (3.2) 15.2 (2.5) 12.0 (3.0) 2-5 45.1 (6.4) 27.7 (3.6) 47.3 (4.8) 46.0 (7.0) Age at onset (<12 years), % 18.9 (3.5) 18.9 (3.5) 18.8 (2.7) 25.6 (4.5) 20.8 (3.3) 29.1 (3.1) 29.2 (3.2) 21.8 (5.5)  Treatment (past years), % Any metal healthcare 48.6 (4.7) Any metal health indicators Any binge eating disorder Any healthcare Any healthcare Any healthcare Any healthcare Any healthcare An						Demographics
18-29 37.4 (5.3) 31.5 (3.6) 24.8 (2.5) 26.0 (3.9) 30-44 36.7 (4.8) 36.7 (4.8) 34.1 (3.8) 38.3 (3.3) 38.8 (4.8) 45-59 16.4 (3.0) 23.2 (3.2) 39.4 (3.0) 30.1 (3.7) ≥ 60 95.(2.4) 11.2 (2.5) 7.7 (1.6) 5.1 (2.1)	< 0.0001 <sup>a,b,d,e,</sup>	79.4 (3.6)	66.5 (3.0)	57.5 (3.6)	51.9 (4.0)	Female, %
30-44 36.7 (4.8) 34.1 (3.8) 38.3 (3.3) 38.8 (4.8) 45-59 16.4 (3.0) 23.2 (3.2) 39.4 (3.0) 30.1 (3.7) 36.0 9.5 (2.4) 11.2 (2.5) 7.7 (1.6) 5.1 (2.1) Clinical characteristics  Number of symptoms, mean 6.3 (0.1) 6.8 (0.1) 9.0 (0.1) 7.9 (0.2) MDD severity (QIDS score), mean 14.3 (0.4) 13.6 (0.3) 16.2 (0.2) 16.3 (0.3) Number of episodes, %  0-1 9.5 (3.0) 23.0 (3.2) 15.2 (2.5) 12.0 (3.0) 2.5 (3.0) 2.5 (3.0) 2.5 (3.0) 2.5 (3.0) 2.5 (3.0) 2.5 (3.0) 2.5 (3.0) 2.5 (3.0) 2.5 (3.0) 2.5 (3.0) 2.5 (3.0) 2.5 (3.0) 2.5 (3.0) 3.0						Age, years: %
45-59   16.4 (3.0)   23.2 (3.2)   39.4 (3.0)   30.1 (3.7)   ≥60   9.5 (2.4)   11.2 (2.5)   7.7 (1.6)   5.1 (2.1)	0.08	26.0 (3.9)	24.8 (2.5)	31.5 (3.6)	37.4 (5.3)	
45-59   16.4 (3.0)   23.2 (3.2)   39.4 (3.0)   30.1 (3.7)   ≥60   9.5 (2.4)   11.2 (2.5)   7.7 (1.6)   5.1 (2.1)		38.8 (4.8)	38.3 (3.3)	34.1 (3.8)	36.7 (4.8)	30–44
Clinical characteristics		30.1 (3.7)	39.4 (3.0)	23.2 (3.2)	16.4 (3.0)	45–59
Number of symptoms, mean  August 20, 10, 10, 10, 10, 10, 10, 10, 10, 10, 1		5.1 (2.1)	7.7 (1.6)	11.2 (2.5)	9.5 (2.4)	≥60
Number of symptoms, mean  Aumber of symptoms, mean  Aumber of symptoms, mean  Aumber of episodes, %  O-1  Age at onset (<12 years), %  Aramily history of MDD, %  Any healthcare  Any healthcare  Any mental healthcare  Any mental healthcare  Any mental healthcare  Any hea						Clinical characteristics
MDD severity (QIDS score), mean  14.3 (0.4)  13.6 (0.3)  16.2 (0.2)  16.3 (0.3)  Number of episodes, %  0-1  0-1  9.5 (3.0)  23.0 (3.2)  15.2 (2.5)  12.0 (3.0)  2-5  45.1 (5.9)  49.3 (3.7)  37.5 (4.1)  41.9 (6.8)  > 5  45.4 (6.4)  27.7 (3.6)  47.3 (4.8)  46.0 (7.0)  Age at onset (<12 years), %  18.9 (3.5)  18.9 (3.5)  18.18 (2.7)  25.6 (4.5)  20.8 (3.3)  Family history of MDD, %  16.7 (3.9)  23.3 (3.8)  30.1 (3.1)  23.0 (5.4)  Family history of mania, %  13.9 (3.4)  19.6 (3.0)  29.2 (3.2)  21.8 (5.5)  Treatment (past years), %  Any healthcare  48.6 (4.7)  40.7 (3.9)  58.5 (2.6)  60.1 (5.5)  Any mental healthcare  35.9 (5.1)  24.1 (2.7)  40.9 (2.3)  32.3 (3.4)  Comorbid psychiatric disorders (past year), %  Mania  3.5 (1.7)  1.1 (0.8)  3.7 (0.9)  3.3 (3.9)  7.0 (2.4)  Hypomania  5.6 (2.1)  7.3 (2.2)  13.3 (2.3)  3.4 (2.0)  Dysthymia  23.4 (4.6)  17.5 (2.5)  29.8 (2.5)  27.2 (3.5)  Generalised anxiety disorder  22.4 (4.1)  21.2 (4.0)  27.3 (2.5)  23.8 (4.0)  Panic disorder  8.0 (2.6)  12.4 (3.9)  18.7 (2.9)  12.5 (2.7)  Social phobia  3.0 (1.6)  4.5 (1.6)  12.0 (1.6)  6.4 (2.6)  Specific phobia  3.0 (1.6)  4.5 (1.6)  12.0 (1.6)  6.4 (2.6)  Specific phobia  3.0 (1.6)  4.5 (1.6)  12.0 (1.6)  4.7 (1.7)  Functional and health indicators  WHO-DAS Functioning, mean  7.7 (0.8)  7.9 (3.4)  7.9 (3.4)  7.9 (3.4)  7.9 (3.4)  7.9 (3.4)  7.9 (3.6)  7.9 (3.4)  7.9 (3.6)  7.9 (3.4)  7.9 (3.6)  7.9 (3.4)  7.9 (3.6)  7.9 (3.4)  7.9 (3.6)  7.9 (3.4)  7.9 (3.6)  7.9 (3.6)  7.9 (3.4)  7.9 (3.6)  7.9 (3.	< 0.0001g	7.9 (0.2)	9.0 (0.1)	6.8 (0.1)	6.3 (0.1)	
Number of episodes, % 0-1 9.5 (3.0) 2-5 45.1 (5.9) 49.3 (3.7) 37.5 (4.1) 41.9 (6.8) 5-5 45.4 (6.4) 27.7 (3.6) 47.3 (4.8) 46.0 (7.0) Age at onset (<12 years), % 18.9 (3.5) 31.8 (2.7) 25.6 (4.5) 20.8 (3.3) 2amily history of MDD, % 16.7 (3.9) 23.3 (3.8) 30.1 (3.1) 23.0 (5.4) 2amily history of mania, % 13.9 (3.4) 19.6 (3.0) 29.2 (3.2) 21.8 (5.5) Treatment (past years), % Any healthcare 48.6 (4.7) 40.7 (3.9) 58.5 (2.6) 60.1 (5.5) Any mental healthcare 35.9 (5.1) 24.1 (2.7) 40.9 (2.3) 32.3 (3.4) 20morbid psychiatric disorders (past year), % Mania 3.5 (1.7) 1.1 (0.8) 3.7 (0.9) 4.2 (3.2) 3.3 (3.4) 2.0 (3.4) 4.0 (3.2) 2.1 (3.5) 3.4 (2.0) 2.1 (3.0) 2.2 (3.2) 3.3 (3.4) 2.2 (3.2) 3.3 (3.4) 2.2 (3.2) 3.3 (3.4) 2.2 (3.2) 3.3 (3.4) 2.3 (3.4) 3.5 (3.1) 3.5 (3.1) 3.7 (0.9) 3.7 (0.9) 3.8 (3.2) 3.8 (3.0) 3.9 (3.0) 3.2 (3.0) 3.2 (3.0) 3.2 (3.0) 3.2 (3.0) 3.2 (3.0) 3.2 (3.0) 3.2 (3.0) 3.2 (3.0) 3.3 (3.0)	< 0.0001 <sup>b,c,d,e</sup>					* ' '
0-1 9.5 (3.0) 23.0 (3.2) 15.2 (2.5) 12.0 (3.0) 2-5 45.1 (5.9) 49.3 (3.7) 37.5 (4.1) 41.9 (6.8) 5-5 45.4 (6.4) 27.7 (3.6) 47.3 (4.8) 46.0 (7.0) 48ge at onset (<12 years), % 18.9 (3.5) 31.8 (2.7) 25.6 (4.5) 20.8 (3.3) 3.7 (3.1) 23.0 (5.4) 47.3 (4.8) 46.0 (7.0) 48ge at onset (<12 years), % 16.7 (3.9) 23.3 (3.8) 30.1 (3.1) 23.0 (5.4) 47.3 (4.8) 46.0 (7.0) 47.3 (4.8) 46.0 (7.0) 47.3 (4.8) 46.0 (7.0) 47.3 (4.8) 46.0 (7.0) 47.3 (4.8) 46.0 (7.0) 47.3 (4.8) 46.0 (7.0) 47.3 (4.8) 46.0 (7.0) 47.3 (4.8) 46.0 (7.0) 47.3 (4.8) 46.0 (7.0) 47.3 (4.8) 46.0 (7.0) 47.3 (4.8	0.015 <sup>a,c,e</sup>		· ,,	(/	- \/	, , ,
2–5 45.1 (5.9) 49.3 (3.7) 37.5 (4.1) 41.9 (6.8) > 5 45.4 (6.4) 27.7 (3.6) 47.3 (4.8) 46.0 (7.0) age at onset (<12 years), % 18.9 (3.5) 31.8 (2.7) 25.6 (4.5) 20.8 (3.3) aramily history of MDD, % 16.7 (3.9) 23.3 (3.8) 30.1 (3.1) 23.0 (5.4) aramily history of mania, % 13.9 (3.4) 19.6 (3.0) 29.2 (3.2) 21.8 (5.5) aramily history of mania, % 13.9 (3.4) 19.6 (3.0) 29.2 (3.2) 21.8 (5.5) arreatment (past years), % 48.6 (4.7) 40.7 (3.9) 58.5 (2.6) 60.1 (5.5) Any mental healthcare 48.6 (4.7) 40.7 (3.9) 58.5 (2.6) 60.1 (5.5) Any mental healthcare 35.9 (5.1) 24.1 (2.7) 40.9 (2.3) 32.3 (3.4) are comorbid psychiatric disorders (past year), % Mania 3.5 (1.7) 1.1 (0.8) 3.7 (0.9) 7.0 (2.4) Hypomania 56 (2.1) 7.3 (2.2) 13.3 (2.3) 3.4 (2.0) Dysthymia 23.4 (4.6) 17.5 (2.5) 29.8 (2.5) 27.2 (3.5) Generalised anxiety disorder 22.4 (4.1) 21.2 (4.0) 27.3 (2.5) 23.8 (4.0) Panic disorder 8.0 (2.6) 12.4 (3.9) 18.7 (2.9) 12.5 (2.7) Social phobia 30.5 (5.5) 15.5 (2.4) 34.0 (2.8) 27.8 (5.0) Agoraphobia 30.0 (1.6) 4.5 (1.6) 12.0 (1.6) 6.4 (2.6) Specific phobia 30.5 (5.5) 15.5 (2.4) 34.0 (2.8) 27.8 (5.0) Agoraphobia 4.6 (3.2) 37.9 (3.4) 26.4 (4.6) Substance use disorder 9.6 (2.7) 8.4 (1.8) 13.3 (2.3) 8.1 (2.8) Any binge eating disorder 2.7 (1.9) 1.0 (0.6) 3.7 (1.1) 4.7 (1.7) are conclusional and health indicators (4.6) 4.0 (4.6)	2.0.0	12.0 (3.0)	15.2 (2.5)	23.0 (3.2)	9.5 (3.0)	. ,
45.4 (6.4) 27.7 (3.6) 47.3 (4.8) 46.0 (7.0) Age at onset (<12 years), % 18.9 (3.5) 31.8 (2.7) 25.6 (4.5) 20.8 (3.3) armly history of MDD, % 16.7 (3.9) 23.3 (3.8) 30.1 (3.1) 23.0 (5.4) armly history of mania, % 13.9 (3.4) 19.6 (3.0) 29.2 (3.2) 21.8 (5.5) areatment (past years), % 48.6 (4.7) 40.7 (3.9) 58.5 (2.6) 60.1 (5.5) Any mental healthcare 48.6 (4.7) 40.7 (3.9) 58.5 (2.6) 60.1 (5.5) Any mental healthcare 35.9 (5.1) 24.1 (2.7) 40.9 (2.3) 32.3 (3.4) 20 armly high psychiatric disorders (past year), % 49.7 (3.9) 58.5 (2.6) 60.1 (5.5) 32.3 (3.4) 20 armly mania 3.5 (1.7) 1.1 (0.8) 3.7 (0.9) 7.0 (2.4) 49.9 (2.3) 32.3 (3.4) 20 armly mania 5.6 (2.1) 7.3 (2.2) 13.3 (2.3) 3.4 (2.0) 20 bysthymia 23.4 (4.6) 17.5 (2.5) 29.8 (2.5) 27.2 (3.5) 32 armly mania 4.6 (3.2) 4.6 (4.1) 21.2 (4.0) 27.3 (2.5) 23.8 (4.0) 27.3 (2.5) 23.8 (4.0) 27.3 (2.5) 23.8 (4.0) 27.3 (2.5) 23.8 (4.0) 27.3 (2.5) 23.8 (4.0) 27.3 (2.5) 27.2 (3.5) 27.2				, ,		
Age at onset (<12 years), % 18.9 (3.5) 31.8 (2.7) 25.6 (4.5) 20.8 (3.3) aramily history of MDD, % 16.7 (3.9) 23.3 (3.8) 30.1 (3.1) 23.0 (5.4) family history of mania, % 13.9 (3.4) 19.6 (3.0) 29.2 (3.2) 21.8 (5.5) areatment (past years), % 7.0 (2.4) 40.7 (3.9) 58.5 (2.6) 60.1 (5.5) Any mental healthcare 48.6 (4.7) 40.7 (3.9) 58.5 (2.6) 60.1 (5.5) Any mental healthcare 35.9 (5.1) 24.1 (2.7) 40.9 (2.3) 32.3 (3.4) comorbid psychiatric disorders (past year), % 35.9 (5.1) 1.1 (0.8) 3.7 (0.9) 7.0 (2.4) Hypomania 5.6 (2.1) 7.3 (2.2) 13.3 (2.3) 3.4 (2.0) Dysthymia 23.4 (4.6) 17.5 (2.5) 29.8 (2.5) 27.2 (3.5) Generalised anxiety disorder 22.4 (4.1) 21.2 (4.0) 27.3 (2.5) 23.8 (4.0) Panic disorder 8.0 (2.6) 12.4 (3.9) 18.7 (2.9) 12.5 (2.7) Social phobia 30.5 (5.5) 15.5 (2.4) 34.0 (2.8) 27.8 (5.0) Agoraphobia 30.1 (6.0 4.5 (1.6) 12.0 (1.6) 6.4 (2.6) Specific phobia 16.7 (3.6) 18.6 (3.2) 37.9 (3.4) 26.4 (4.6) Substance use disorder 9.6 (2.7) 8.4 (1.8) 13.3 (2.3) 8.1 (2.8) Any binge eating disorder 2.7 (1.9) 1.0 (0.6) 3.7 (1.1) 4.7 (1.7) cunctional and health indicators WHO-DAS Functioning, mean 7.7 (0.8) 7.9 (1.4) 13.9 (0.8) 9.0 (1.4) heehan Disability Scale (% severe/very severe), mean 59.9 (5.4) 56.2 (4.4) 74.3 (3.3) 67.2 (5.3) 10.0 (3.0) mass index, kg/m²: mean 26.7 (0.6) 26.7 (0.6) 27.4 (0.4) 30.1 (0.6) chronic diseases, % Heart attack 3.2 (1.6) 1.2 (0.9) 6.1 (1.5) 3.0 (1.8) Heart disease 7.0 (2.1) 2.9 (1.3) 5.3 (1.4) 7.2 (2.7) High blood pressure 28.7 (5.2) 29.7 (2.9) 28.5 (4.6)						
Tamily history of MDD, % Tamily history of mania, % Treatment (past years), % Any healthcare Any healthcare Any healthcare Any mental healthcare Any high earlier disorders (past year), % Ania Any high earlier disorder Any disorder Any high earlier disorder Any binge eating disorder Any b	0.016 <sup>b,c</sup>	, ,				
Family history of mania, % 13.9 (3.4) 19.6 (3.0) 29.2 (3.2) 21.8 (5.5) are extment (past years), % 13.9 (3.4) 19.6 (3.0) 29.2 (3.2) 21.8 (5.5) are extment (past years), % 24.1 (2.7) 24.1 (2.7) 24.0 (2.3) 32.3 (3.4) 25.0 (2.6) 24.1 (2.7) 25.1 (2.7) 25.1	0.12					
Any healthcare 48.6 (4.7) 40.7 (3.9) 58.5 (2.6) 60.1 (5.5) Any mental healthcare 35.9 (5.1) 24.1 (2.7) 40.9 (2.3) 32.3 (3.4) (2.0) (2.0) (2.0) (2.3) 32.3 (3.4) (2.0) (2	0.03 <sup>b</sup>					
Any healthcare 48.6 (4.7) 40.7 (3.9) 58.5 (2.6) 60.1 (5.5) Any mental healthcare 35.9 (5.1) 24.1 (2.7) 40.9 (2.3) 32.3 (3.4) comorbid psychiatric disorders (past year), %  Mania 3.5 (1.7) 1.1 (0.8) 3.7 (0.9) 7.0 (2.4) Hypomania 5.6 (2.1) 7.3 (2.2) 13.3 (2.3) 3.4 (2.0) Dysthymia 23.4 (4.6) 17.5 (2.5) 29.8 (2.5) 27.2 (3.5) Generalised anxiety disorder 22.4 (4.1) 21.2 (4.0) 27.3 (2.5) 23.8 (4.0) Panic disorder 8.0 (2.6) 12.4 (3.9) 18.7 (2.9) 12.5 (2.7) Social phobia 30.5 (5.5) 15.5 (2.4) 34.0 (2.8) 27.8 (5.0) Agoraphobia 30.0 (1.6) 4.5 (1.6) 12.0 (1.6) 6.4 (2.6) Specific phobia 16.7 (3.6) 18.6 (3.2) 37.9 (3.4) 26.4 (4.6) Substance use disorder 9.6 (2.7) 8.4 (1.8) 13.3 (2.3) 8.1 (2.8) Any binge eating disorder 2.7 (1.9) 1.0 (0.6) 3.7 (1.1) 4.7 (1.7) cunctional and health indicators (4.6) Heart and health indicators (4.6) (4.7) (4.6) (4.7)	0.00	21.0 (0.0)	27.2 (0.2)	17.0 (0.0)	10.7 (0.4)	
Any mental healthcare 35.9 (5.1) 24.1 (2.7) 40.9 (2.3) 32.3 (3.4) comorbid psychiatric disorders (past year), %  Mania 3.5 (1.7) 1.1 (0.8) 3.7 (0.9) 7.0 (2.4) Hypomania 5.6 (2.1) 7.3 (2.2) 13.3 (2.3) 3.4 (2.0) Dysthymia 23.4 (4.6) 17.5 (2.5) 29.8 (2.5) 27.2 (3.5) Generalised anxiety disorder 22.4 (4.1) 21.2 (4.0) 27.3 (2.5) 23.8 (4.0) Panic disorder 8.0 (2.6) 12.4 (3.9) 18.7 (2.9) 12.5 (2.7) Social phobia 30.5 (5.5) 15.5 (2.4) 34.0 (2.8) 27.8 (5.0) Agoraphobia 30.1 (6.6) 4.5 (1.6) 12.0 (1.6) 6.4 (2.6) Specific phobia 16.7 (3.6) 18.6 (3.2) 37.9 (3.4) 26.4 (4.6) Substance use disorder 9.6 (2.7) 8.4 (1.8) 13.3 (2.3) 8.1 (2.8) Any binge eating disorder 2.7 (1.9) 1.0 (0.6) 3.7 (1.1) 4.7 (1.7) cunctional and health indicators (HO-DAS Functioning, mean 7.7 (0.8) 7.9 (1.4) 13.9 (0.8) 9.0 (1.4) heehan Disability Scale (% severe/very severe), mean 59.9 (5.4) 56.2 (4.4) 74.3 (3.3) 67.2 (5.3) ody mass index, kg/m²: mean 26.7 (0.6) 26.7 (0.6) 27.4 (0.4) 30.1 (0.6) heart attack 3.2 (1.6) 1.2 (0.9) 6.1 (1.5) 3.0 (1.8) Heart disease 7.0 (2.1) 2.9 (1.3) 5.3 (1.4) 7.2 (2.7) High blood pressure 28.7 (5.2) 19.4 (2.9) 28.5 (4.6)	0.0009 <sup>e</sup>	60.1 (5.5)	58 5 (2.6)	40.7 (3.9)	48 6 (4 7)	
Mania 3.5 (1.7) 1.1 (0.8) 3.7 (0.9) 7.0 (2.4) Hypomania 5.6 (2.1) 7.3 (2.2) 13.3 (2.3) 3.4 (2.0) Dysthymia 23.4 (4.6) 17.5 (2.5) 29.8 (2.5) 27.2 (3.5) Generalised anxiety disorder 22.4 (4.1) 21.2 (4.0) 27.3 (2.5) 23.8 (4.0) Panic disorder 8.0 (2.6) 12.4 (3.9) 18.7 (2.9) 12.5 (2.7) Social phobia 30.5 (5.5) 15.5 (2.4) 34.0 (2.8) 27.8 (5.0) Agoraphobia 30.1 (6.6) 4.5 (1.6) 12.0 (1.6) 6.4 (2.6) Specific phobia 16.7 (3.6) 18.6 (3.2) 37.9 (3.4) 26.4 (4.6) Substance use disorder 9.6 (2.7) 8.4 (1.8) 13.3 (2.3) 8.1 (2.8) Any binge eating disorder 2.7 (1.9) 1.0 (0.6) 3.7 (1.1) 4.7 (1.7) Functional and health indicators WHO-DAS Functioning, mean 7.7 (0.8) 7.9 (1.4) 13.9 (0.8) 9.0 (1.4) heehan Disability Scale (% severe/very severe), mean 59.9 (5.4) 56.2 (4.4) 74.3 (3.3) 67.2 (5.3) sody mass index, kg/m²: mean 59.9 (5.4) 56.2 (4.4) 74.3 (3.3) 67.2 (5.3) hordy mass index, kg/m²: mean 26.7 (0.6) 26.7 (0.6) 27.4 (0.4) 30.1 (0.6) chronic diseases, % Heart attack 3.2 (1.6) 1.2 (0.9) 6.1 (1.5) 3.0 (1.8) Heart disease 7.0 (2.1) 2.9 (1.3) 5.3 (1.4) 7.2 (2.7) High blood pressure 28.7 (5.2) 19.4 (2.9) 28.4 (2.9) 28.5 (4.6)	0.0006 <sup>c,f</sup>					•
Mania       3.5 (1.7)       1.1 (0.8)       3.7 (0.9)       7.0 (2.4)         Hypomania       5.6 (2.1)       7.3 (2.2)       13.3 (2.3)       3.4 (2.0)         Dysthymia       23.4 (4.6)       17.5 (2.5)       29.8 (2.5)       27.2 (3.5)         Generalised anxiety disorder       22.4 (4.1)       21.2 (4.0)       27.3 (2.5)       23.8 (4.0)         Panic disorder       8.0 (2.6)       12.4 (3.9)       18.7 (2.9)       12.5 (2.7)         Social phobia       30.5 (5.5)       15.5 (2.4)       34.0 (2.8)       27.8 (5.0)         Agoraphobia       3.0 (1.6)       4.5 (1.6)       12.0 (1.6)       6.4 (2.6)         Specific phobia       16.7 (3.6)       18.6 (3.2)       37.9 (3.4)       26.4 (4.6)         Substance use disorder       9.6 (2.7)       8.4 (1.8)       13.3 (2.3)       8.1 (2.8)         Any binge eating disorder       9.6 (2.7)       8.4 (1.8)       13.3 (2.3)       8.1 (2.8)         Any binge eating disorder       2.7 (1.9)       1.0 (0.6)       3.7 (1.1)       4.7 (1.7)         Functional and health indicators       4.40       4.40       4.40       4.40       4.40       4.40       4.40       4.40       4.40       4.40       4.40       4.40       4.40       4.40       4.4			· ·			•
Hypomania 5.6 (2.1) 7.3 (2.2) 13.3 (2.3) 3.4 (2.0) Dysthymia 23.4 (4.6) 17.5 (2.5) 29.8 (2.5) 27.2 (3.5) Generalised anxiety disorder 22.4 (4.1) 21.2 (4.0) 27.3 (2.5) 23.8 (4.0) Panic disorder 8.0 (2.6) 12.4 (3.9) 18.7 (2.9) 12.5 (2.7) Social phobia 30.5 (5.5) 15.5 (2.4) 34.0 (2.8) 27.8 (5.0) Agoraphobia 3.0 (1.6) 4.5 (1.6) 12.0 (1.6) 6.4 (2.6) Specific phobia 16.7 (3.6) 18.6 (3.2) 37.9 (3.4) 26.4 (4.6) Substance use disorder 9.6 (2.7) 8.4 (1.8) 13.3 (2.3) 8.1 (2.8) Any binge eating disorder 9.6 (2.7) 8.4 (1.8) 13.3 (2.3) 8.1 (2.8) Any binge eating disorder 2.7 (1.9) 1.0 (0.6) 3.7 (1.1) 4.7 (1.7) Sunctional and health indicators WHO-DAS Functioning, mean 7.7 (0.8) 7.9 (1.4) 13.9 (0.8) 9.0 (1.4) heehan Disability Scale (% severe/very severe), mean 59.9 (5.4) 56.2 (4.4) 74.3 (3.3) 67.2 (5.3) ody mass index, kg/m²: mean 59.9 (5.4) 56.2 (4.4) 74.3 (3.3) 67.2 (5.3) hronic diseases, %  Heart attack 3.2 (1.6) 1.2 (0.9) 6.1 (1.5) 3.0 (1.8) Heart disease 7.0 (2.1) 2.9 (1.3) 5.3 (1.4) 7.2 (2.7) High blood pressure 28.7 (5.2) 19.4 (2.9) 28.4 (2.9) 28.5 (4.6)	0.054	7 (2 4)	3.7 (0.9)	1 1 (0.8)	3 5 (1 7)	1 3 11
Dysthymia     23.4 (4.6)     17.5 (2.5)     29.8 (2.5)     27.2 (3.5)       Generalised anxiety disorder     22.4 (4.1)     21.2 (4.0)     27.3 (2.5)     23.8 (4.0)       Panic disorder     8.0 (2.6)     12.4 (3.9)     18.7 (2.9)     12.5 (2.7)       Social phobia     30.5 (5.5)     15.5 (2.4)     34.0 (2.8)     27.8 (5.0)       Agoraphobia     3.0 (1.6)     4.5 (1.6)     12.0 (1.6)     6.4 (2.6)       Specific phobia     16.7 (3.6)     18.6 (3.2)     37.9 (3.4)     26.4 (4.6)       Substance use disorder     9.6 (2.7)     8.4 (1.8)     13.3 (2.3)     8.1 (2.8)       Any binge eating disorder     2.7 (1.9)     1.0 (0.6)     3.7 (1.1)     4.7 (1.7)       Functional and health indicators       VHO-DAS Functioning, mean     7.7 (0.8)     7.9 (1.4)     13.9 (0.8)     9.0 (1.4)       heehan Disability Scale (% severe/very severe), mean     59.9 (5.4)     56.2 (4.4)     74.3 (3.3)     67.2 (5.3)       ody mass index, kg/m²: mean     26.7 (0.6)     26.7 (0.6)     27.4 (0.4)     30.1 (0.6)       hronic diseases, %       Heart attack     3.2 (1.6)     1.2 (0.9)     6.1 (1.5)     3.0 (1.8)       Heart disease     7.0 (2.1)     2.9 (1.3)     5.3 (1.4)     7.2 (2.7)       High blood pressure     28.7 (5.2)	0.013 <sup>b,c,f</sup>					
Generalised anxiety disorder 22.4 (4.1) 21.2 (4.0) 27.3 (2.5) 23.8 (4.0) Panic disorder 8.0 (2.6) 12.4 (3.9) 18.7 (2.9) 12.5 (2.7) Social phobia 30.5 (5.5) 15.5 (2.4) 34.0 (2.8) 27.8 (5.0) Agoraphobia 3.0 (1.6) 4.5 (1.6) 12.0 (1.6) 6.4 (2.6) Specific phobia 16.7 (3.6) 18.6 (3.2) 37.9 (3.4) 26.4 (4.6) Substance use disorder 9.6 (2.7) 8.4 (1.8) 13.3 (2.3) 8.1 (2.8) Any binge eating disorder 2.7 (1.9) 1.0 (0.6) 3.7 (1.1) 4.7 (1.7) Sunctional and health indicators WHO-DAS Functioning, mean 7.7 (0.8) 7.9 (1.4) 13.9 (0.8) 9.0 (1.4) heehan Disability Scale (% severe/very severe), mean 26.7 (0.6) 26.7 (0.6) 27.4 (0.4) 30.1 (0.6) hronic diseases, % Heart attack 3.2 (1.6) 1.2 (0.9) 6.1 (1.5) 3.0 (1.8) Heart disease 7.0 (2.1) 2.9 (1.3) 5.3 (1.4) 7.2 (2.7) High blood pressure 28.7 (5.2) 19.4 (2.9) 28.4 (2.9) 28.5 (4.6)	0.011°					21
Panic disorder 8.0 (2.6) 12.4 (3.9) 18.7 (2.9) 12.5 (2.7) Social phobia 30.5 (5.5) 15.5 (2.4) 34.0 (2.8) 27.8 (5.0) Agoraphobia 3.0 (1.6) 4.5 (1.6) 12.0 (1.6) 6.4 (2.6) Specific phobia 16.7 (3.6) 18.6 (3.2) 37.9 (3.4) 26.4 (4.6) Substance use disorder 9.6 (2.7) 8.4 (1.8) 13.3 (2.3) 8.1 (2.8) Any binge eating disorder 2.7 (1.9) 1.0 (0.6) 3.7 (1.1) 4.7 (1.7) Functional and health indicators (7.7 (0.8) 7.9 (1.4) 13.9 (0.8) 9.0 (1.4) heehan Disability Scale (% severe/very severe), mean 59.9 (5.4) 56.2 (4.4) 74.3 (3.3) 67.2 (5.3) ody mass index, kg/m²: mean 26.7 (0.6) 26.7 (0.6) 27.4 (0.4) 30.1 (0.6) hronic diseases, % Heart attack 3.2 (1.6) 1.2 (0.9) 6.1 (1.5) 3.0 (1.8) Heart disease 7.0 (2.1) 2.9 (1.3) 5.3 (1.4) 7.2 (2.7) High blood pressure 28.7 (5.2) 19.4 (2.9) 28.4 (2.9) 28.5 (4.6)	0.55					, ,
Social phobia         30.5 (5.5)         15.5 (2.4)         34.0 (2.8)         27.8 (5.0)           Agoraphobia         3.0 (1.6)         4.5 (1.6)         12.0 (1.6)         6.4 (2.6)           Specific phobia         16.7 (3.6)         18.6 (3.2)         37.9 (3.4)         26.4 (4.6)           Substance use disorder         9.6 (2.7)         8.4 (1.8)         13.3 (2.3)         8.1 (2.8)           Any binge eating disorder         2.7 (1.9)         1.0 (0.6)         3.7 (1.1)         4.7 (1.7)           Functional and health indicators         (HO-DAS Functioning, mean         7.7 (0.8)         7.9 (1.4)         13.9 (0.8)         9.0 (1.4)           heehan Disability Scale (% severe/very severe), mean         59.9 (5.4)         56.2 (4.4)         74.3 (3.3)         67.2 (5.3)           ody mass index, kg/m²: mean         26.7 (0.6)         26.7 (0.6)         27.4 (0.4)         30.1 (0.6)           hronic diseases, %         Heart attack         3.2 (1.6)         1.2 (0.9)         6.1 (1.5)         3.0 (1.8)           Heart disease         7.0 (2.1)         2.9 (1.3)         5.3 (1.4)         7.2 (2.7)           High blood pressure         28.7 (5.2)         19.4 (2.9)         28.4 (2.9)         28.5 (4.6)	0.11					,
Agoraphobia 3.0 (1.6) 4.5 (1.6) 12.0 (1.6) 6.4 (2.6) Specific phobia 16.7 (3.6) 18.6 (3.2) 37.9 (3.4) 26.4 (4.6) Substance use disorder 9.6 (2.7) 8.4 (1.8) 13.3 (2.3) 8.1 (2.8) Any binge eating disorder 2.7 (1.9) 1.0 (0.6) 3.7 (1.1) 4.7 (1.7) Functional and health indicators (4.7 (1.9) 4.7 (1.9)	0.0014 <sup>c</sup>					
Specific phobia         16.7 (3.6)         18.6 (3.2)         37.9 (3.4)         26.4 (4.6)           Substance use disorder         9.6 (2.7)         8.4 (1.8)         13.3 (2.3)         8.1 (2.8)           Any binge eating disorder         2.7 (1.9)         1.0 (0.6)         3.7 (1.1)         4.7 (1.7)           Functional and health indicators         7.7 (0.8)         7.9 (1.4)         13.9 (0.8)         9.0 (1.4)           Pho-DAS Functioning, mean         7.7 (0.8)         7.9 (1.4)         13.9 (0.8)         9.0 (1.4)           heehan Disability Scale (% severe/very severe), mean         59.9 (5.4)         56.2 (4.4)         74.3 (3.3)         67.2 (5.3)           ody mass index, kg/m²: mean         26.7 (0.6)         26.7 (0.6)         27.4 (0.4)         30.1 (0.6)           chronic diseases, %         Heart attack         3.2 (1.6)         1.2 (0.9)         6.1 (1.5)         3.0 (1.8)           Heart disease         7.0 (2.1)         2.9 (1.3)         5.3 (1.4)         7.2 (2.7)           High blood pressure         28.7 (5.2)         19.4 (2.9)         28.4 (2.9)         28.5 (4.6)	0.0027 <sup>b,c</sup>					·
Substance use disorder 9.6 (2.7) 8.4 (1.8) 13.3 (2.3) 8.1 (2.8) Any binge eating disorder 2.7 (1.9) 1.0 (0.6) 3.7 (1.1) 4.7 (1.7)  Functional and health indicators  WHO-DAS Functioning, mean 7.7 (0.8) 7.9 (1.4) 13.9 (0.8) 9.0 (1.4) heehan Disability Scale (% severe/very severe), mean 59.9 (5.4) 56.2 (4.4) 74.3 (3.3) 67.2 (5.3) ody mass index, kg/m²: mean 26.7 (0.6) 26.7 (0.6) 27.4 (0.4) 30.1 (0.6) hronic diseases, %  Heart attack 3.2 (1.6) 1.2 (0.9) 6.1 (1.5) 3.0 (1.8) Heart disease 7.0 (2.1) 2.9 (1.3) 5.3 (1.4) 7.2 (2.7) High blood pressure 28.7 (5.2) 19.4 (2.9) 28.4 (2.9) 28.5 (4.6)	< 0.0027					0 1
Any binge eating disorder 2.7 (1.9) 1.0 (0.6) 3.7 (1.1) 4.7 (1.7) 4.7 (1.7) 4.7 (1.7) 4.7 (1.7) 5 (1.7	0.20					·
Functional and health indicators  WHO-DAS Functioning, mean  7.7 (0.8)  7.9 (1.4)  13.9 (0.8)  9.0 (1.4)  13.9 (0.8)  9.0 (1.4)  13.9 (0.8)  9.0 (1.4)  13.9 (0.8)  9.0 (1.4)  13.9 (0.8)  9.0 (1.4)  13.9 (0.8)  9.0 (1.4)  13.9 (0.8)  9.0 (1.4)  13.9 (0.8)  9.0 (1.4)  13.9 (0.8)  9.0 (1.4)  13.9 (0.8)  9.0 (1.4)  13.9 (0.8)  9.0 (1.4)  13.9 (0.8)  14.0 (3.2)  15.0 (	0.24					
/HO-DAS Functioning, mean 7.7 (0.8) 7.9 (1.4) 13.9 (0.8) 9.0 (1.4) heehan Disability Scale (% severe/very severe), mean 59.9 (5.4) 56.2 (4.4) 74.3 (3.3) 67.2 (5.3) ody mass index, kg/m²: mean 26.7 (0.6) 26.7 (0.6) 27.4 (0.4) 30.1 (0.6) hronic diseases, %  Heart attack 3.2 (1.6) 1.2 (0.9) 6.1 (1.5) 3.0 (1.8) Heart disease 7.0 (2.1) 2.9 (1.3) 5.3 (1.4) 7.2 (2.7) High blood pressure 28.7 (5.2) 19.4 (2.9) 28.4 (2.9) 28.5 (4.6)	0.27	T., (1.,)	0.7 (1.17	1.0 (0.0)	2.7 (1.7)	
heehan Disability Scale (% severe/very severe), mean 59.9 (5.4) 56.2 (4.4) 74.3 (3.3) 67.2 (5.3) ody mass index, kg/m²: mean 26.7 (0.6) 26.7 (0.6) 27.4 (0.4) 30.1 (0.6) chronic diseases, %  Heart attack 3.2 (1.6) 1.2 (0.9) 6.1 (1.5) 3.0 (1.8) Heart disease 7.0 (2.1) 2.9 (1.3) 5.3 (1.4) 7.2 (2.7) High blood pressure 28.7 (5.2) 19.4 (2.9) 28.4 (2.9) 28.5 (4.6)	< 0.0001 <sup>b,c,t</sup>	9 0 (1 1)	13.9 (0.8)	7 9 (1 1)	77 (0.8)	
dody mass index, kg/m²: mean     26.7 (0.6)     26.7 (0.6)     27.4 (0.4)     30.1 (0.6)       chronic diseases, %       Heart attack     3.2 (1.6)     1.2 (0.9)     6.1 (1.5)     3.0 (1.8)       Heart disease     7.0 (2.1)     2.9 (1.3)     5.3 (1.4)     7.2 (2.7)       High blood pressure     28.7 (5.2)     19.4 (2.9)     28.4 (2.9)     28.5 (4.6)	0.003°					<u>.</u>
hronic diseases, % Heart attack Heart disease 7.0 (2.1) High blood pressure  3.2 (1.6) 1.2 (0.9) 6.1 (1.5) 3.0 (1.8) 7.2 (2.7) 2.9 (1.3) 5.3 (1.4) 7.2 (2.7) 19.4 (2.9) 28.4 (2.9) 28.5 (4.6)	< 0.003			, ,		
Heart attack     3.2 (1.6)     1.2 (0.9)     6.1 (1.5)     3.0 (1.8)       Heart disease     7.0 (2.1)     2.9 (1.3)     5.3 (1.4)     7.2 (2.7)       High blood pressure     28.7 (5.2)     19.4 (2.9)     28.4 (2.9)     28.5 (4.6)	₹0.0001	30.1 (0.0)	27.4 (0.4)	20.7 (0.0)	20.7 (0.0)	
Heart disease       7.0 (2.1)       2.9 (1.3)       5.3 (1.4)       7.2 (2.7)         High blood pressure       28.7 (5.2)       19.4 (2.9)       28.4 (2.9)       28.5 (4.6)	0.09	3 0 /1 8/	61(15)	1 2 (0 0)	3 2 (1 4)	· · · · · · · · · · · · · · · · · · ·
High blood pressure 28.7 (5.2) 19.4 (2.9) 28.4 (2.9) 28.5 (4.6)	0.09					
	0.32			, ,		
						9
	0.27					
Migraine     10.5 (3.3)     11.9 (2.6)     19.2 (3.1)     16.2 (3.6)       Other headache     27.4 (5.2)     31.0 (2.9)     34.5 (2.7)     37.1 (4.3)	0.08 0.35					8

MDD, major depressive disorder; QIDS, Quick Inventory of Depressive Symptomatology; WHO-DAS, World Health Organization Disability Assessment Schedule.

atypical symptom pattern, including increased appetite, weight gain and fatigue (atypical). The structure of depression among adults displayed more heterogeneity, with four subtypes instead of the three found in adolescents. Two of the three subtypes in adolescents - severe typical and atypical - had symptom patterns identical to those in adults. Although the more complex presentation of depression in adults could illustrate developmental changes in depression parallel to those witnessed in the transition between childhood and adolescence, 44 it could also be in part an artefact of the lack of a clear-cut distinction between the moderate typical and moderate classes.

# **Subtypes and correlates**

Our findings further confirm prior classification studies that have demonstrated the importance of inclusion of a severity

component in subtyping depression in both adults and adolescents. 14,20,21 Compared with moderate groups, the severe groups were distinguished by a greater number of depressive symptoms, number of depressive episodes, symptom severity, treatment and role impairment in both adults and young people. Evidence for distinctions between subgroups by severity highlights the importance of implementing a dimensional severity rating for improving depression diagnosis. Aside from severity, the subtypes were also distinguished by differential symptom profiles. The typical subtype was the most prevalent subtype (approximately 70%) in both adults and adolescents. Although we did not assess all melancholic symptoms, the severe typical subtype that we identified was characterised by the core features of melancholia including more loss of appetite and weight loss, psychomotor change and feelings of guilt (the latter being more pronounced

a. Class 1 significantly different from class 2, P < 0.05. b. Class 1 significantly different from class 3, P < 0.05.

c. Class 2 significantly different from class 3, P < 0.05. d. Class 4 significantly different from class 1, P < 0.05.

e. Class 4 significantly different from class 3, P < 0.05. f. Class 4 significantly different from class 3, P < 0.05. g. All classes significantly different, P < 0.05.

in the adult sample). Typical/melancholic subtypes have also been identified in several LCA studies in the USA and The Netherlands. $^{20,21}$ 

The atypical subtype, demonstrated in numerous clinical and community samples of adults, 12-23 has not previously been examined in community studies of adolescents. 45,46 prevalence of the atypical subtype in adults with depression (16%) was similar to that in one prior LCA study,<sup>20</sup> but somewhat higher than has been generally found in other studies. However, the much higher prevalence of the subtype in adolescents with depression (26%) was well within the range reported from clinical samples of adolescents with depression (25-47%). 45,46 Correlates of the atypical subtype were similar to those found in previous research. The female preponderance, increased rates of bipolar spectrum and anxiety disorders in adults, and higher BMI scores have been found in both clinical and community samples. 20,43,47,48 As demonstrated by previous studies, 47,49 adolescents with this subtype more often had any binge eating disorder compared with those with the moderate type. This association is not surprising given the conceptual overlap between the two conditions. The earlier finding that the atypical subtype is associated with metabolic syndrome - a cluster of risk factors for cardiovascular disease and diabetes - suggests the importance of the somatic component in atypical depression.<sup>20</sup> Therefore, the presentation of this subtype in adolescence provides an important target for developing assessment and treatment strategies that address possible somatic and metabolic abnormalities as well.

Overall, change in appetite was the most potent indicator that seemed to differentiate between subtypes. Interestingly, several previous studies using factor analysis found an appetite/weight factor, with positive factor loadings for increased appetite and weight, and negative loadings for decreased appetite and weight, suggesting that variations in appetite and weight are defining features of depression that may distinguish between affected individuals.<sup>7,44</sup> Indeed, the atypical subtype observed in both adolescents and adults was primarily defined by appetite and weight gain, as has been also shown in prior work. <sup>14,20,21,43</sup>

# **Limitations**

This study has several limitations that should be considered when interpreting the results. First, the conditional branching inherent in the CIDI may have led to an underestimation of atypical symptoms. Skip rules were used in the interview for questions assessing changes in appetite or weight, changes in sleep and psychomotor changes, so that if one symptom was present (for example, decreased appetite), the question to assess its reverse (increased appetite) was not administered. Because some individuals present with different symptoms in different episodes, or even present with both variants during the same episode, this study may have underestimated the true prevalence of atypical depression. Nevertheless, our results are highly comparable to LCAs of data where skips were not used.<sup>20</sup> Second, some variables, including number of episodes and family history, had substantial numbers of missing values. Third, only DSM-IV criterion symptoms were used in this study; other symptoms of depression that might be present in adolescents, such as irritability, were not included. Fourth, although the DSM-IV definition of atypical depression requires the presence of mood reactivity (in addition to two or more of the symptoms of weight gain or increased appetite, hypersomnia, leaden paralysis and interpersonal rejection sensitivity), it was not included in our LCA because no information on mood reactivity was available in NCS-A and NCS-R. The atypical subtype therefore does not strictly adhere to the DSM-IV criteria. However, the hierarchical DSM-IV

definition of atypical depression has been debated in adults and adolescents. 45,47 In addition, mood reactivity did not play an important part in distinguishing subtypes in one previous LCA study. 20

# **Implications**

These findings provide new insights into subtypes of depression in adolescents. With respect to nosology, when taken together with previous research regarding distinct biological correlates, 20,24,26,50 and treatment response of the atypical subtype, <sup>22,23,51</sup> our findings support retention of the atypical specifier in the DSM-5. As shown previously by Leventhal et al<sup>29</sup> and others, these results also demonstrate that specific subgroups of depression can be distinguished in community samples of adolescents. These subgroups appear similar to those identified in clinical samples of young people as well as both clinical and community samples of adults. Although these symptom profiles in adults and adolescents display substantial overlap, this does not provide evidence of continuity of profiles from adolescence to adulthood. Several studies of depression in both adults and adolescents have demonstrated that the stability of subtypes and symptoms appears low, 9,11,52 and that a substantial proportion of young adults even meet criteria for different subtypes simultaneously.<sup>53</sup> Because subtype stability may be essential to its clinical usefulness, future research is needed to evaluate the continuity and correlates of subtypes over time. Increased understanding of the subtypes of depression in adolescence may also enhance our ability to provide timely and effective treatment, particularly because a substantial proportion of adolescents with depression do not respond to evidence-based treatment,<sup>54</sup> and episode recurrence is common. 55,56 Longitudinal research might also help to identify the timing of changes across subtypes that could inform the optimal timing of intervention.

Femke Lamers, PhD, Marcy Burstein, PhD, Jian-ping He, MSc, Genetic Epidemiology Research Branch, Intramural Research Program, National Institute of Mental Health (NIMH), Bethesda, Maryland, USA; Shelli Avenevoli, PhD, Division of Developmental Translational Research, NIMH, Bethesda, Maryland, USA; Jules Angst, MD, Zürich University Psychiatric Hospital, Zürich, Switzerland; Kathleen R. Merikangas, PhD, Genetic Epidemiology Research Branch, Intramural Research Program, NIMH, Bethesda, Maryland, USA

Correspondence: Dr Kathleen R. Merikangas, National Institutes of Health, National Institute of Mental Health, 35 Convent Drive, MSC 3720, Bethesda, MD 20892-3720, USA. Email: Kathleen.Merikangas@nih.gov

First received 21 Jun 2011, final revision 4 Nov 2011, accepted 13 Feb 2012

# **Funding**

The study was supported by the Intramural Research Program of the National Institute of Mental Health (Z01 MH002808-08). The National Comorbidity Survey (NCS) Adolescent Supplement and the larger programme of related NCS surveys are supported by the National Institute of Mental Health (U01-MH60220). The views and opinions expressed in this article are those of the authors and should not be construed to represent the views of any of the sponsoring organisations, agencies or the US government. F.L. is supported by a Rubicon Fellowship from The Netherlands Organisation for Scientific Research (NWO).

# References

- 1 Cohen P, Cohen J, Kasen S, Velez CN, Hartmark C, Johnson J, et al. An epidemiological study of disorders in late childhood and adolescence I. Ageand gender-specific prevalence. J Child Psychol Psychiatry 1993; 34: 851–67.
- 2 Cole DA, Tram JM, Martin JM, Hoffman KB, Ruiz MD, Jacquez FM, et al. Individual differences in the emergence of depressive symptoms in children and adolescents: a longitudinal investigation of parent and child reports. J Abnorm Psychol 2002; 111: 156–65.
- 3 Feehan M, McGee R, Raja SN, Williams SM. DSM-III-R disorders in New Zealand 18-year-olds. *Aust N Z J Psychiatry* 1994; **28**: 87–99.
- 4 Kovacs M, Feinberg TL, Crouse-Novak M, Paulauskas SL, Pollock M, Finkelstein R. Depressive disorders in childhood. II. A longitudinal study of the risk for a subsequent major depression. Arch Gen Psychiatry 1984; 41: 643–9.

- 5 Simonoff E, Pickles A, Meyer JM, Silberg JL, Maes HH, Loeber R, et al. The Virginia Twin Study of Adolescent Behavioral Development. Influences of age, sex, and impairment on rates of disorder. *Arch Gen Psychiatry* 1997; 54: 801–8.
- 6 Wittchen HU, Nelson CB, Lachner G. Prevalence of mental disorders and psychosocial impairments in adolescents and young adults. *Psychol Med* 1998; 28: 109–26.
- 7 Ryan ND, Puig-Antich J, Ambrosini P, Rabinovich H, Robinson D, Nelson B, et al. The clinical picture of major depression in children and adolescents. Arch Gen Psychiatry 1987; 44: 854–61.
- 8 Strober M, Green J, Carlson G. Phenomenology and subtypes of major depressive disorder in adolescence. *J Affect Disord* 1981: 3: 281–90.
- 9 Lewinsohn PM, Pettit JW, Joiner TE, Seeley JR. The symptomatic expression of major depressive disorder in adolescents and young adults. J Abnorm Psychol 2003; 112: 244–52.
- 10 Weiss B, Garber J. Developmental differences in the phenomenology of depression. Dev Psychopathol 2003; 15: 403–30.
- 11 Roberts RE, Lewinsohn PM, Seeley JR. Symptoms of DSM-III-R major depression in adolescence: evidence from an epidemiological survey. J Am Acad Child Adolesc Psychiatry 1995; 34: 1608–17.
- 12 Carlson GA, Kashani JH. Phenomenology of major depression from childhood through adulthood: analysis of three studies. Am J Psychiatry 1988; 145: 1222–5
- 13 Kovacs M. Presentation and course of major depressive disorder during childhood and later years of the life span. J Am Acad Child Adolesc Psychiatry 1996; 35: 705–15.
- 14 Kendler KS, Eaves □, Walters EE, Neale MC, Heath AC, Kessler RC. The identification and validation of distinct depressive syndromes in a population-based sample of female twins. Arch Gen Psychiatry 1996; 53: 391–9.
- 15 Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry 2002; 7: 254–75.
- 16 Parker G, Brotchie H. Psychomotor change as a feature of depressive disorders: an historical overview. Aust N Z J Psychiatry 1992; 26: 146–55.
- 17 Merikangas KR, Wicki W, Angst J. Heterogeneity of depression. Classification of depressive subtypes by longitudinal course. Br J Psychiatry 1994; 164: 342–8.
- 18 Nierenberg AA, Trivedi MH, Fava M, Biggs MM, Shores-Wilson K, Wisniewski SR, et al. Family history of mood disorder and characteristics of major depressive disorder: a STAR\*D (sequenced treatment alternatives to relieve depression) study. *J Psychiatr Res* 2007; 41: 214–21.
- 19 Baumeister H, Parker G. Meta-review of depressive subtyping models. J Affect Disord 2011; in press, doi: 10.1016/j.jad.2011.07.015.
- 20 Lamers F, de Jonge P, Nolen WA, Smit JH, Zitman FG, Beekman AT, et al. Identifying depressive subtypes in a large cohort study: results from the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry 2010; 71: 1582–9.
- 21 Sullivan PF, Kessler RC, Kendler KS. Latent class analysis of lifetime depressive symptoms in the national comorbidity survey. Am J Psychiatry 1998; 155: 1398–406.
- 22 West ED, Dally PJ. Effects of iproniazid in depressive syndromes. BMJ 1959; 1: 1491–4.
- 23 Quitkin FM, Stewart JW, McGrath PJ, Liebowitz MR, Harrison WM, Tricamo E, et al. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 1988; 145: 306–11.
- 24 Asnis GM, McGinn LK, Sanderson WC. Atypical depression: clinical aspects and noradrenergic function. *Am J Psychiatry* 1995; 152: 31–6.
- 25 Gold PW, Chrousos GP. The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. *Proc Assoc Am Physicians* 1999; 111: 22–34.
- 26 Posternak MA. Biological markers of atypical depression. Harv Rev Psychiatry 2003; 11: 1–7.
- 27 Coryell W, Winokur G, Shea T, Maser JD, Endicott J, Akiskal HS. The long-term stability of depressive subtypes. Am J Psychiatry 1994; 151: 199–204.
- 28 Coryell W, Winokur G, Maser JD, Akiskal HS, Keller MB, Endicott J. Recurrently situational (reactive) depression: a study of course, phenomenology and familial psychopathology. J Affect Disord 1994; 31: 203–10.
- 29 Leventhal AM, Pettit JW, Lewinsohn PM. Characterizing major depression phenotypes by presence and type of psychomotor disturbance in adolescents and young adults. *Depress Anxiety* 2008; 25: 575–92.
- 30 Kessler RC, Merikangas KR. The National Comorbidity Survey Replication (NCS-R): background and aims. Int J Methods Psychiatr Res 2004; 13: 60-8.

- 31 Kessler RC, Avenevoli S, Costello EJ, Green JG, Gruber MJ, Heeringa S, et al. National comorbidity survey replication adolescent supplement (NCS-A): II. Overview and design. J Am Acad Child Adolesc Psychiatry 2009: 48: 380–5.
- 32 Merikangas KR, He JP, Burstein M, Swanson SA, Avenevoli S, Cui L, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication–Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry 2010; 49: 980–9.
- 33 Kessler RC, Ustun TB. The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res 2004; 13: 93–121.
- 34 Merikangas K, Avenevoli S, Costello J, Koretz D, Kessler RC. National comorbidity survey replication adolescent supplement (NCS-A): I. Background and measures. J Am Acad Child Adolesc Psychiatry 2009; 48: 367–9.
- 35 Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. *Biol Psychiatry* 2003; 54: 573–83.
- 36 Chwastiak LA, Von Korff M. Disability in depression and back pain: evaluation of the World Health Organization Disability Assessment Schedule (WHO DAS II) in a primary care setting. J Clin Epidemiol 2003; 56: 507–14.
- 37 Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med 1997; 27: 93–105.
- 38 Schoenborn CA, Adams PF, Schiller JS. Summary health statistics for the US population: National Health Interview Survey, 2000. Vital Health Stat 10 2003; 214: 1–83.
- 39 Muthén LK, Muthén B. Mplus User's Guide (6th edn). Muthén & Muthén, 1997–2010.
- **40** Nylund KL, Asparouhov T, Muthen B. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. *Struct Equ Modeling* 2007; **14**: 535–69.
- 41 Yang CC. Evaluating latent class analysis models in qualitative phenotype identification. *Comput Stat Data Anal* 2006; **50**: 1090–104.
- 42 Neuman RJ, Todd RD, Heath AC, Reich W, Hudziak JJ, Bucholz KK, et al. Evaluation of ADHD typology in three contrasting samples: a latent class approach. J Am Acad Child Adolesc Psychiatry 1999; 38: 25–33.
- 43 Sullivan PF, Prescott CA, Kendler KS. The subtypes of major depression in a twin registry. *J Affect Dis* 2002; **68**: 273–84.
- **44** Yorbik O, Birmaher B, Axelson D, Williamson DE, Ryan ND. Clinical characteristics of depressive symptoms in children and adolescents with major depressive disorder. *J Clin Psychiatry* 2004; **65**: 1654–9.
- 45 Williamson DE, Birmaher B, Brent DA, Balach L, Dahl RE, Ryan ND. Atypical symptoms of depression in a sample of depressed child and adolescent outpatients. J Am Acad Child Adolesc Psychiatry 2000; 39: 1253–9.
- 46 Klein RG, Mannuzza S, Koplewicz HS, Tancer NK, Shah M, Liang V, et al. Adolescent depression: controlled desipramine treatment and atypical features. *Depress Anxiety* 1998; 7: 15–31.
- 47 Angst J, Gamma A, Benazzi F, Silverstein B, Ajdacic-Gross V, Eich D, et al. Atypical depressive syndromes in varying definitions. Eur Arch Psychiatry Clin Neurosci 2006; 256: 44–54.
- 48 Matza LS, Revicki DA, Davidson JR, Stewart JW. Depression with atypical features in the National Comorbidity Survey: classification, description, and consequences. Arch Gen Psychiatry 2003; 60: 817–26.
- 49 Posternak MA, Zimmerman M. Partial validation of the atypical features subtype of major depressive disorder. Arch Gen Psychiatry 2002; 59: 70-6.
- 50 Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. *Psychosom Med* 2011; 73: 114–26.
- 51 Stewart JW, Thase ME. Treating DSM-IV depression with atypical features. J Clin Psychiatry 2007; 68: e10.
- 52 Nandi A, Beard JR, Galea S. Epidemiologic heterogeneity of common mood and anxiety disorders over the lifecourse in the general population: a systematic review. BMC Psychiatry 2009; 9: 31.
- 53 Angst J, Gamma A, Benazzi F, Ajdacic V, Rossler W. Melancholia and atypical depression in the Zurich study: epidemiology, clinical characteristics, course, comorbidity and personality. Acta Psychiatr Scand Suppl 2007; 433: 72–84.
- 54 March J, Silva S, Vitiello B. The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks. J Am Acad Child Adolesc Psychiatry 2006; 45: 1393–403.
- 55 Lewinsohn PM, Allen NB, Seeley JR, Gotlib IH. First onset versus recurrence of depression: differential processes of psychosocial risk. J Abnorm Psychol 1999: 108: 483–9.
- 56 Rao U, Hammen C, Daley SE. Continuity of depression during the transition to adulthood: a 5-year longitudinal study of young women. J Am Acad Child Adolesc Psychiatry 1999; 38: 908–15.